Breaking News Instant updates and real-time market news.

UNH

UnitedHealth

$222.77

-2.66 (-1.18%)

, GSK

GlaxoSmithKline

$37.65

0.29 (0.78%)

08:00
03/13/18
03/13
08:00
03/13/18
08:00

UnitedHealth: Andrew Witty to become Optum CEO July 1

UNH

UnitedHealth

$222.77

-2.66 (-1.18%)

GSK

GlaxoSmithKline

$37.65

0.29 (0.78%)

  • 13

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    May

UNH UnitedHealth
$222.77

-2.66 (-1.18%)

03/13/18
ADAM
03/13/18
NO CHANGE
Target $90
ADAM
Buy
Insulet improved market access reinforces growth opportunity, says Canaccord
Canaccord analyst Kyle Rose noted UnitedHealth (UNH) has agreed to cover the Insulet (PODD) OmniPod for its 70M covered lives. The announcement provides a meaningful growth opportunity for 2018 and beyond. The increased market access reinforces his conviction that Insulet remains in the early stages of a transformative period of meaningful market share gains. Rose reiterated his Buy rating and raised his price target to $90 from $88 on Insulet shares.
03/12/18
WBLR
03/12/18
NO CHANGE
WBLR
Outperform
Insulet announced coverage win with UnitedHealth, says William Blair
Insulet (PODD) on Friday announced it had established a new contract with UnitedHealthcare (UNH), which would provide its patients with in-network, durable medical equipment coverage for Omnipod beginning April 1, William Blair analyst Margaret Kaczor tells investors in a research note. This is another coverage win for Insulet as UnitedHealth represents almost 50M lives in the United States, the analyst adds. She notes Insulet has had limited access to historically a Medtronic (MDT) has been UnitedHealth's preferred, in-network DME insulin pump provider since mid-2016. Kaczor views the announcement as "another improvement in patient access to Omnipod." She thinks Insulet "continues to fire on all cylinders" and keeps an Outperform rating on the shares.
03/10/18
PIPR
03/10/18
NO CHANGE
Target $88
PIPR
Overweight
Insulet scores 'nice win' at UnitedHealth into weekend, says Piper Jaffray
Insulet (PODD) and UnitedHealth (UNH) announced yesterday afternoon an in-network contract for Omnipod which goes into effect April 1, Piper Jaffray analyst JP McKim tells investors in a research note. Omnipod is Insulet's tubeless insulin pump to monitor type 1 diabetes. The agreement affects commercial and Medicaid lives, the analyst points out. He views the news as a "nice win" for Insulet and expects the shares to react favorably. McKim continues to recommend Insulet with an Overweight rating and sees the stock pushing towards his $88 price target. The shares closed Friday up 67c to $80.33.
03/08/18
PIPR
03/08/18
NO CHANGE
Target $226
PIPR
Overweight
Cigna deal for Express Scripts makes Medicaid or MA deal less likely, says Piper Jaffray
Piper Jaffray analyst Sarah James said she does not see any issues with Cigna (CI) obtaining approval of its deal to buy Express Scripts (ESRX), even though the deal will give the combined company annual script volume of 848M, making it the third-largest PBM. She does not think Cigna's script volume would transition to the combined entity until 2023, which is when Cigna's contract with UnitedHealth's (UNH) OptumRx ends. Also, James thinks this deal makes it less likely in the near-term that Cigna would buy a Medicaid or Medicare Advantage plan. The analyst has an Overweight rating and $226 price target on Cigna shares.
GSK GlaxoSmithKline
$37.65

0.29 (0.78%)

02/22/18
LEER
02/22/18
NO CHANGE
LEER
Rapid adoption of Gilead Biktarvy to challenge GlaxoSmithKline outlook, says Leerink
Leerink analyst Seamus Fernandez notes he has recently completed a MEDACorp survey of U.S. HIV treatment specialists and has found "impressively positive" sentiment about Gilead's (GILD) Biktarvy which seems likely to put sustained pressure on GlaxoSmithKline's (GSK) leading integrase inhibitor Tivicay, as well as cannibalizing Gilead's other combination and component products.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$103.54

1.2 (1.17%)

11:45
03/21/19
03/21
11:45
03/21/19
11:45
Options
PayPal call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$37.75

-0.12 (-0.32%)

11:38
03/21/19
03/21
11:38
03/21/19
11:38
Conference/Events
Boston Scientific management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    May

  • 28

    May

ORHOF

Origin House

$0.00

(0.00%)

, ACB

Aurora Cannabis

$9.60

-0.2 (-2.04%)

11:38
03/21/19
03/21
11:38
03/21/19
11:38
On The Fly
Rising High: An exclusive talk with cannabis brands company Origin House »

In this edition of…

ORHOF

Origin House

$0.00

(0.00%)

ACB

Aurora Cannabis

$9.60

-0.2 (-2.04%)

APHA

Aphria

$9.98

-0.15 (-1.48%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$20.67

-0.59 (-2.78%)

CGC

Canopy Growth

$45.90

-0.9 (-1.92%)

TLRY

Tilray

$69.93

-0.7 (-0.99%)

IGC

India Globalization Capital

$2.02

0.12 (6.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

ORTFD

Biome Grow

$0.00

(0.00%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

MMNFF

MedMen

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

FB

Facebook

$164.56

-0.91 (-0.55%)

11:37
03/21/19
03/21
11:37
03/21/19
11:37
Hot Stocks
Facebook says issues fixed after finding user passwords readable by employees »

Facebook's VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

11:36
03/21/19
03/21
11:36
03/21/19
11:36
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

11:36
03/21/19
03/21
11:36
03/21/19
11:36
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:35
03/21/19
03/21
11:35
03/21/19
11:35
General news
U.S. equities have ramped higher »

U.S. equities have ramped…

SRC

Spirit Realty

$37.60

0.54 (1.46%)

11:31
03/21/19
03/21
11:31
03/21/19
11:31
Conference/Events
Spirit Realty management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 09

    May

WFC

Wells Fargo

$49.32

-1.07 (-2.12%)

, GS

Goldman Sachs

$193.30

-0.97 (-0.50%)

11:27
03/21/19
03/21
11:27
03/21/19
11:27
Periodicals
Wells Fargo in talks to hire former Goldman co-COO as its CEO, NY Post reports »

Wells Fargo (WFC) is in…

WFC

Wells Fargo

$49.32

-1.07 (-2.12%)

GS

Goldman Sachs

$193.30

-0.97 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Apr

  • 23

    Apr

  • 28

    May

  • 13

    Jul

  • 12

    Oct

FB

Facebook

$165.28

-0.19 (-0.11%)

11:26
03/21/19
03/21
11:26
03/21/19
11:26
Periodicals
Facebook stored user passwords in plain text for years, KrebsOnSecurity says »

Hundreds of millions of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

WDC

Western Digital

$50.60

3.43 (7.27%)

11:25
03/21/19
03/21
11:25
03/21/19
11:25
Options
Western Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
03/21/19
03/21
11:25
03/21/19
11:25
General news
Treasury Action: the yield curve is a big topic of conversation »

Treasury Action: the…

11:25
03/21/19
03/21
11:25
03/21/19
11:25
Conference/Events
JPMorgan medtech analyst to hold a group luncheon »

Medtech Analyst Marcus…

PEB

Pebblebrook Hotel

$32.07

0.34 (1.07%)

11:21
03/21/19
03/21
11:21
03/21/19
11:21
Conference/Events
Pebblebrook Hotel management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 28

    Mar

  • 29

    Mar

BIIB

Biogen

$230.10

-90.37 (-28.20%)

11:21
03/21/19
03/21
11:21
03/21/19
11:21
Downgrade
Biogen rating change  »

Biogen downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

AGCO

Agco

$68.12

0.15 (0.22%)

11:20
03/21/19
03/21
11:20
03/21/19
11:20
Conference/Events
Agco management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

IEX

IDEX Corp.

$150.73

2.31 (1.56%)

11:19
03/21/19
03/21
11:19
03/21/19
11:19
Conference/Events
IDEX Corp. management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

ITGR

Integer

$85.72

0.28 (0.33%)

11:18
03/21/19
03/21
11:18
03/21/19
11:18
Conference/Events
Integer management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 02

    Apr

  • 03

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
03/21/19
03/21
11:17
03/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EB

Eventbrite

$20.84

0.75 (3.73%)

11:16
03/21/19
03/21
11:16
03/21/19
11:16
Conference/Events
Eventbrite management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
03/21/19
03/21
11:16
03/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCL

Royal Caribbean

$116.64

0.55 (0.47%)

11:15
03/21/19
03/21
11:15
03/21/19
11:15
Options
Royal Caribbean put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
03/21/19
03/21
11:15
03/21/19
11:15
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:15
03/21/19
03/21
11:15
03/21/19
11:15
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:15
03/21/19
03/21
11:15
03/21/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.